28 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net … or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net … or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
relationships, and there will be no offset against the amounts due Executive under this Agreement, except as specifically provided in Section 6(c
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any … are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
due to a net loss of $7,380,793, offset by stock-based compensation expense of $1,733,233, shares issued for license of $2,225,733, a change in account … used in operating activities was $1,567,149. The cash flow used in operating activities resulted from the net loss of $2,458,589, primarily offset
424B3
h0n6qzmmna
16 Apr 24
Prospectus supplement
5:45pm
10-K
g6hxldxr8v9 vnlj
16 Apr 24
Annual report
4:48pm
424B4
0lye7rw3oub62h
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
03f2jf1ko
20 Feb 24
Prospectus supplement with pricing info
5:28pm